Identifying Low-Risk Patients With Pulmonary Embolism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00086151|
Recruitment Status : Completed
First Posted : June 29, 2004
Last Update Posted : July 29, 2016
|Condition or disease|
|Pulmonary Embolism Lung Diseases|
Pulmonary embolism (PE) is a common, costly, and potentially lethal disease in the US. While patients with PE are almost universally treated as inpatients and their length of hospital stay (LOS) varies widely, there is evidence that outpatient care with low-molecular-weight heparins or early discharge of hospitalized patients are effective and safe options for up to 50% of patients with PE. However, physicians may be reluctant to treat patients with PE on an outpatient basis or with brief hospitalization when the perceived risk of mortality or experiencing a short-term adverse outcome is not well quantified. The study will develop a clinical prediction rule to identify patients with acute pulmonary embolism who are at very low risk for short-term adverse outcomes.
The retrospective cohort study will develop a clinical prediction rule that accurately identifies low-risk patients with PE who are potential candidates for outpatient care or early discharge. The specific aims are 1) to derive a clinical prediction rule that identifies patients with PE who have a very low 30-day mortality risk (<= 2%), and 2) to assess the performance of this rule in predicting other relevant outcomes (i.e., major bleeding, respiratory failure [RF], cardiogenic shock, cardiac arrest) or processes of care (i.e., thrombolysis, mechanical ventilation [MV], intensive care unit (ICU) admission, length of hospital stay, hospital readmission).
The study uses 3 large and reliable databases, the PHC4 database, the MediQual Atlas database, and the National Death Index (NDI). These databases contain a rich set of clinical information and outcomes data. The prediction rule for prognosis will be derived from 8,000 patients discharged with a diagnosis of PE from all acute care hospitals in Pennsylvania during the calendar years 2000-2001. Patients with PE will be identified using primary ICD-9-CM discharge codes for PE or secondary discharge codes for PE coupled with primary discharge codes that represent complications or treatments of PE. Baseline data that include 35 potential clinical predictors of short-term mortality in PE will be abstracted from the PHC4/Atlas databases.
The primary outcome will be 30-day mortality ascertained from the NDI; secondary outcomes will be major bleeding, respiratory failure, cardiogenic shock, cardiac arrest, thrombolysis, mechanical ventilation, ICU admission, length of hospital stay, and readmission. Classification tree analysis will be used to construct a simple clinical prediction rule that identifies a 20% subgroup of all patients with a 30-day mortality rate of 2% or less. The predictive accuracy of this rule will be externally validated in an independent cohort of 4,000 patients with PE from calendar year 2002 using identical patient identification strategies as for the derivation cohort. The safety of this rule will be tested in the validation cohort by computing the proportion of very low-risk patients who die within 30-days or have another adverse outcome. This innovative application will derive a clinical prediction rule for prognosis that has the potential to improve the cost-effectiveness of the management for PE. The long-term goal of this project will be to validate and implement this rule in prospective studies to test its safety and effectiveness and to establish future admission/early hospital discharge recommendations for patients with PE.
|Study Type :||Observational|
|Study Start Date :||July 2004|
|Primary Completion Date :||June 2007|
|Study Completion Date :||June 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00086151
|OverallOfficial:||Drahomir Aujesky||University of Pittsburgh|